SCHEMBL24253498

SCHEMBL24253498

CCCc1ccc2c(c1)CN(C)CC2

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 3/20 0.51
DRD3 P35462 3/20 0.51
MAOA P21397 4/20 0.48
MAOB P27338 4/20 0.48
SLC6A4 P31645 1/20 0.46
HTR2C P28335 3/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
HTR2A P28223 1/20 0.44
CYP2C19 P33261 1/20 0.44
HTR6 P50406 1/20 0.44
CHRNA7 P36544 2/20 0.43
DRD1 P21728 1/20 0.42
DRD5 P21918 1/20 0.42
TLR7 Q9NYK1 1/20 0.42
HRH3 Q9Y5N1 1/20 0.41
HTR2B P41595 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22993389 0.93 DRD2 (0.49) DRD2DRD3MAOAMAOBSLC6A4
SCHEMBL24329573 0.87 HTR2C (0.48) DRD2DRD3MAOAMAOBSLC6A4
SCHEMBL10066156 0.86 MAOA (0.52) DRD2DRD3MAOAMAOBSLC6A4
SCHEMBL20939408 0.81 DRD2 (0.55) DRD2DRD3HTR2CCYP1A2CYP3A4
SCHEMBL10039921 0.81 MAOA (0.55) DRD2DRD3MAOAMAOBSLC6A4
SCHEMBL22541985 0.81 MAOA (0.51) DRD2DRD3MAOAMAOBSLC6A4
SCHEMBL12683145 0.81 MAOA (0.50) DRD2DRD3MAOAMAOBSLC6A4
SCHEMBL8227369 0.79 ESR1 (0.54) DRD2DRD3HTR2CCYP1A2CYP3A4
SCHEMBL8203535 0.79 NOTUM (0.56) CYP1A2CYP2C9CYP2C19HRH3
SCHEMBL14419145 0.78 HRH3 (0.49) DRD2DRD3MAOAMAOBSLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230250080-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LTD (GB) 2023-08-10 US disclosed
US-11613527-B2 Enzyme inhibitors KALVISTA PHARMACEUTICALS LIMITED (GB) 2023-03-28 US disclosed
US-20220048894-A1 ENZYME INHIBITORS KALVISTA PHARMACEUTICALS LIMITED (GB) 2022-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250080-A1 ENZYME INHIBITORS SERPINB1, KLKB1, SERPINE1 DRD2 4189/4885DRD3 3841/4885MAOA 175/4885
US-11613527-B2 Enzyme inhibitors SERPINB1, KLKB1, SERPINE1 DRD2 4189/4885DRD3 3841/4885MAOA 175/4885
US-20220048894-A1 ENZYME INHIBITORS SERPINB1, KLKB1, SERPINE1 DRD2 4189/4885DRD3 3841/4885MAOA 175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.